Vaccines targeting TAAs have been developed in HCC vaccine-based therapy to identify a growing number of TAAs, including alpha-fetoprotein (AFP), GPC-3, and telomerase-reverse transcriptase (TERT). This evidence concerns the gene AFP and hepatocellular carcinoma.